Literature DB >> 10507785

HPV testing in primary screening of older women.

J Cuzick1, E Beverley, L Ho, G Terry, H Sapper, I Mielzynska, A Lorincz, W K Chan, T Krausz, P Soutter.   

Abstract

Certain types of the human papilloma virus (HPV) are well established as the primary cause of cervical cancer. Several studies have shown that HPV testing can improve the detection rate of high-grade cervical intraepithelial neoplasia (CIN), but these have been carried out primarily in younger women. In this study we evaluated the role of HPV testing as an adjunct to cytology in women aged 35 or over. An additional aim was to evaluate commercially available kits for HPV testing. A total of 2988 eligible women aged 34 or more attending for a routine smear in 40 general practitioner practices received HPV testing in addition to routine cytology, after having given written informed consent. Samples were assayed by polymerase chain reaction (PCR) and two versions of the Hybrid Capture test for HPV, and women were invited for colposcopy if there was any cytological abnormality (including borderline smears) or the PCR test was positive. Any apparent abnormality was biopsied and loop-excision was performed as necessary. CIN was judged by histology; 42 women had high-grade CIN, of which six were cytology negative (86% sensitivity for borderline or worse) and three had a borderline smear (79% sensitivity for mild dyskaryosis or worse). The positive predictive value of a borderline smear was only 3.1%. Eleven high-grade lesions were negative by the PCR HPV test (sensitivity 74%). The first generation Hybrid Capture II test had a similar sensitivity but an unacceptably high false positive rate (18.3%), while the newer Hybrid Capture II microtitre kit had a 95% sensitivity and a 2.3% positivity rate in normal women when used at a 2 pg ml(-1) cut-off (positive predictive value 27%). Cytology performed very well in this older cohort of women. The newer Hybrid Capture II microtitre test may be a useful adjunct, especially if the results reported here are reproducible in other studies. A combined screening test offers the possibility of greater protection and/or longer screening intervals, which could reduce the overall cost of the screening programme.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507785      PMCID: PMC2362918          DOI: 10.1038/sj.bjc.6690730

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses.

Authors:  W K Kinney; M M Manos; L B Hurley; J E Ransley
Journal:  Obstet Gynecol       Date:  1998-06       Impact factor: 7.661

2.  Semiautomated detection of human papillomavirus DNA of high and low oncogenic potential in cervical smears.

Authors:  G Terry; L Ho; A Szarewski; J Cuzick
Journal:  Clin Chem       Date:  1994-10       Impact factor: 8.327

3.  Persistence of type-specific human papillomavirus infection among cytologically normal women.

Authors:  A Hildesheim; M H Schiffman; P E Gravitt; A G Glass; C E Greer; T Zhang; D R Scott; B B Rush; P Lawler; M E Sherman
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

4.  Mild cervical dyskaryosis: safety of cytological surveillance.

Authors:  M H Jones; D Jenkins; J Cuzick; M R Wolfendale; J J Jones; C Balogun-Lynch; M M Usherwood; A Singer
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

5.  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance.

Authors:  J T Cox; A T Lorincz; M H Schiffman; M E Sherman; A Cullen; R J Kurman
Journal:  Am J Obstet Gynecol       Date:  1995-03       Impact factor: 8.661

6.  Should patients with mild atypia in a cervical smear be referred for colposcopy?

Authors:  W P Soutter; S Wisdom; A K Brough; J M Monaghan
Journal:  Br J Obstet Gynaecol       Date:  1986-01

7.  Long term follow up of women with borderline cervical smear test results: effects of age and viral infection on progression to high grade dyskaryosis.

Authors:  L Hirschowitz; A E Raffle; E F Mackenzie; A O Hughes
Journal:  BMJ       Date:  1992-05-09

8.  An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy.

Authors:  K D Hatch; A Schneider; M W Abdel-Nour
Journal:  Am J Obstet Gynecol       Date:  1995-04       Impact factor: 8.661

9.  Human papillomavirus testing in primary cervical screening.

Authors:  J Cuzick; A Szarewski; G Terry; L Ho; A Hanby; P Maddox; M Anderson; G Kocjan; S T Steele; J Guillebaud
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

10.  Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia.

Authors:  J Cuzick; G Terry; L Ho; T Hollingworth; M Anderson
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more
  47 in total

1.  Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study.

Authors:  G Rebello; N Hallam; G Smart; D Farquharson; J McCafferty
Journal:  BMJ       Date:  2001-04-14

Review 2.  Recent advances: Sexually transmitted infections.

Authors:  R J Gilson; A Mindel
Journal:  BMJ       Date:  2001-05-12

3.  Lower Genital Tract Infections and HIV in Women.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

4.  Method for testing for human papillomavirus infection in patients with cervical intraepithelial disease.

Authors:  Hsing-Pei Lin; Yang-Yang Huang; Hsueh-Yin Wu; Jau-Tsuen Kao
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 5.  Recent trends in the epidemiology of sexually transmitted infections in the European Union.

Authors:  K A Fenton; C M Lowndes
Journal:  Sex Transm Infect       Date:  2004-08       Impact factor: 3.519

6.  Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.

Authors:  Maria T Sandri; Paola Lentati; Elvira Benini; Patrizia Dell'Orto; Laura Zorzino; Francesca M Carozzi; Patrick Maisonneuve; Rita Passerini; Michela Salvatici; Chiara Casadio; Sara Boveri; Mario Sideri
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

7.  Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types.

Authors:  Tarik Gheit; Stefano Landi; Federica Gemignani; Peter J F Snijders; Salvatore Vaccarella; Silvia Franceschi; Federico Canzian; Massimo Tommasino
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

8.  Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media.

Authors:  Ted E Schutzbank; Charlene Jarvis; Nicole Kahmann; Katherine Lopez; Marlea Weimer; Aleta Yount
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

9.  Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Authors:  C Estrade; P-A Menoud; D Nardelli-Haefliger; R Sahli
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

10.  Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women.

Authors:  Sotirios Tsiodras; John Georgoulakis; Aikaterini Chranioti; Zanis Voulgaris; Amanda Psyrri; Angeliki Tsivilika; John Panayiotides; Petros Karakitsos
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.